Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma Research Letter

   


Authors: Zinzani, P. L.; Salles, G.; Moskowitz, A. J.; Santoro, A.; Mehta, A.; Barr, P. M.; Mehta-Shah, N.; Collins, G. P.; Ansell, S. M.; Brody, J. D.; Domingo-Domenech, E.; Johnson, N. A.; Cunningham, D.; Ferrari, S.; Lisano, J.; Krajewski, J.; Wen, R.; Akyol, A.; Crowe, R.; Savage, K. J.
Title: Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
Keywords: immunohistochemistry; adult; protein expression; aged; major clinical study; overall survival; fatigue; neutropenia; systemic therapy; follow up; letter; clinical practice; cohort analysis; practice guideline; pneumonia; cutaneous t cell lymphoma; peripheral t cell lymphoma; programmed death 1 ligand 1; brentuximab vedotin; nivolumab; human
Journal Title: Blood Advances
Volume: 8
Issue: 10
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2024-05-28
Start Page: 2400
End Page: 2404
Language: English
DOI: 10.1182/bloodadvances.2023011030
PUBMED: 38531062
PROVIDER: scopus
PMCID: PMC11112622
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195168150&doi=10.1182%2fbloodadvances.2023011030&partnerID=40&md5=d1224fb5652072989d35b0f86d06b8da
Notes: Letter -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Alison Moskowitz
    339 Moskowitz
  2. Gilles Andre Salles
    269 Salles
Related MSK Work